| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Pathology, University of Erlangen-Nürnberg, Erlangen, Germany
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
However, there is increasing evidence that APC gene mutations alone are not responsible for the increased nuclear expression of ß-catenin. For instance, most colorectal carcinomas show a heterogenous distribution pattern of nuclear ß-catenin, suggesting additional genetic or epigenic events regulating ß-catenin distribution.8,9 On the other hand, ß-catenin-independent functions of APC gene mutations are suggested for early colorectal carcinogenesis.10
Because some of the identified ß-catenin target genes are potentially associated with proliferation, we wanted to correlate the proliferative activity, nuclear ß-catenin expression, and the expression of the target gene c-myc in colon adenoma. We used a collection of 88 different cases, from small, early to late colon adenoma with beginning invasive growth, for immunohistochemical analysis. The results revealed i) a highly heterogenous expression pattern of nuclear ß-catenin, with the most significant correlation of nuclear ß-catenin and c-myc expression not with the grade of dysplasia but with the size of the colon adenoma; ii) a perfect correlation of nuclear ß-catenin and c-myc expression; iii) no significant correlation of adenoma size with the proliferative activity; and iv) no significant correlation of proliferative activity and the nuclear expression of ß-catenin and c-myc. These results have impact on the functions of APC gene mutations and nuclear ß-catenin in early colon carcinogenesis.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Formalin-fixed, paraffin-embedded tissues from patients who underwent polypectomy were retrieved from the archive of the Institute for Pathology, University of Erlangen-Nürnberg. All adenomas were totally removed, and the size was determined after formalin fixation. The 88 investigated colorectal adenomas had a size distribution from 2 to 25 mm in diameter, with 33 showing mild, 37 showing medium, and 18 showing severe grades of dysplasia. To exclude statistical results based simply on the strong correlation between adenoma size and grades of dysplasia, normally found in colorectal adenomas, high-grade dysplastic small adenomas and low-grade dysplastic large adenomas were also included in the collective.
Immunohistochemistry
Serial sections (3 µmol/L) were deparaffinized, rehydrated, and
incubated with the different mouse monoclonal antibodies for 2 hours.
Antigen retrieval was used for 
-mib-1 and -c-myc
(microwave treatment, 10 minutes at 800 W and 10 minutes at 600 W).
Dilutions were 1:30 for -mib-1 (Dako, Hamburg, Germany), 1:200 for
anti-c-myc (clone 9E11 from Novocastra, Newcastle, UK), and
1:100 for -ß-catenin (Transduction Laboratories, Lexington, KY).
Biotinylated rabbit -mouse Ig antiserum diluted 1:50 was used as the
secondary antibody. After washing, the slides were incubated for 30
minutes. at room temperature with streptavidin-coupled alkaline
phosphatase (Dako) and developed for 12 minutes at 37°C, using Fast
Red (Sigma, Deisenhofen, Germany) as substrate. After rinsing in water,
the sections were counterstained with hemalaun (Merck, Darmstadt,
Germany), dehydrated, and coverslipped.
Evaluation of Immunostaining
The sections were examined by two independent researchers. Normal colonic epithelia adjacent to the adenomas were used as internal controls of staining efficiency and evaluation. Because the nuclear expression of ß-catenin and c-myc was never homogeneous but varied in both intensity and distribution in the adenomas, we used a scoring system that included an evaluation of both the staining intensity and the percentage of stained cells. Staining intensity was graded as no staining (value 0, as in normal colonic epithelia), weak staining (value 1), moderate staining (value 2), or strong staining (value 3). The percentages of tumor cells with nuclear staining of ß-catenin and c-myc were assigned scores as follows: 1, <5%; 2, 5–20%; 3, 21–50%; 4, >50%. Multiplication of the intensity value and the percentage value gave a multiplication value from 0 to 12. The multiplication values were grouped in four immunoreactive scores defined as 0 (negative; multiplication values 0, 1), 1 (low; multiplication values 2, 3), 2 (medium; multiplication values 4, 6), or 3 (high; multiplication values 8, 9, 12). For the proliferative activity, we determined the percentage of mib-1-positive tumor cells and scored 0, <5%; 1, 5–20%; 2, 21–50%; and 3, >50% mib-1-positive cells. Because the proliferative activity of normal colon epithelium was scored as 1, no adenoma was scored as 0.
Statistics
Statistical analysis was performed with the SPSS software (SPSS
Standard version 8.0.0, SPSS Inc., Chicago, IL). The correlations
between absolute size (in millimeters) and immunoreactivity were
evaluated by the Mann-Whitney U test. The correlations among sizes,
groups, and grades of dysplasia with immunoreactivity were evaluated by
2
test (linear-by-linear association).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Statistical analysis confirmed a very strong correlation
(P < 0.001) of nuclear
ß-catenin-immunoreactive scores 0, 1, and 2 with tumor size. Median
adenoma diameters were 3, 7, 13, and 17 mm for the scores 0, 1, 2, and
3, respectively (Figure 1A)
. According to
the observation that c-myc is a target gene of
ß-catenin/TCF4, we found an almost identical correlation of nuclear
c-myc expression with adenoma size; median adenoma diameters
were 3.5, 7.2, 14, and 18 mm for the immunoreactive scores 0, 1, 2, and
3, respectively (Figure 1B)
. It is interesting that we found no
significant correlation of the proliferative activity with the size of
the adenomas (Figure 1C)
and, therefore, not with nuclear ß-catenin
and c-myc expression.
|
. Of the adenomas <5 mm in
size, 92% showed no nuclear ß-catenin expression, and no case in
this size group had medium (2) or high (3) immunoreactive scores. In
contrast, all examined adenomas >8 mm in size showed nuclear
overexpression of ß-catenin, with scores of 2 or 3. We also defined
an intermediate size group between 5 and 8 mm with beginning and
increasing expression of nuclear ß-catenin. The statistical
significance of these results was again very high
(P < 0.001). As expected, we again found almost
identical correlations of the defined three size groups with
c-myc expression (P < 0.001; Table 2
) and no significant correlation with
the proliferative activity (Table 3)
.
|
|
|
. Again, we
also found a correlation with c-myc expression (Table 5)
and no significant correlation with
proliferative activity (Table 6)
.
However, compared with the statistical significance of the correlations
with adenoma size (P < 0.001), the correlation
of nuclear ß-catenin and c-myc with the grade of dysplasia
was weaker (P < 0.005). The adenomas that were
<5 mm in size with severe dysplasia did not express nuclear
ß-catenin and c-myc.
|
|
|
). In contrast, many cases of
tumor cells in the mib-1-positive proliferative area did not express
nuclear ß-catenin or c-myc (Figure 2, A
-C) and vice versa
(Figure 2, D
-F). Thus, as has been shown statistically, for the whole
collection of adenomas there was no perfect, spatial correlation
between immunohistochemically detectable nuclear ß-catenin or
c-myc and the proliferative active zones in the individual
adenomas.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The functional consequence of the strong correlation between nuclear ß-catenin amounts and the adenoma size must be discussed critically, because already low amounts of immunohistochemically undetectable transcriptional activators could be functionally active. However, we also found a perfect correlation between the expression level of nuclear ß-catenin and its target gene c-myc in individual adenomas, which implies a direct dependence of the amounts of expressed c-myc on the concentration of nuclear ß-catenin. This is also confirmed by functional analyses in cell culture, in which the transcriptional activity of ß-catenin target gene promoters depends on the amounts of ß-catenin (T. Brabletz, A. Jung, and T. Kirchner, unpublished data). Recent results could explain this dose-dependent function of ß-catenin. Without nuclear ß-catenin, TCF proteins are bound by a corepressor, as demonstrated for the repressor groucho in Drosophila species, and this complex acts as transcriptional repressor of the target genes.12,13 Nuclear ß-catenin competes with the repressor for TCF binding in a dose-dependent manner. Higher amounts of ß-catenin could build up more activator complexes, which would lead to a more efficient de-repression of the target genes. Furthermore, it was demonstrated that high amounts of ß-catenin are necessary to overcome a repression of TCF activity by the histone acetylase C-terminal-binding protein.14 Thus, the concentration of nuclear ß-catenin is an important parameter.
We detected no significant correlation between the nuclear expression of ß-catenin or c-myc and proliferative activity. This was demonstrated both for large adenomas, in which highly proliferative areas often did not show nuclear ß-catenin, and for strongly proliferating small adenomas, which did not express detectable amounts of nuclear ß-catenin and c-myc at all. The question is how hyperproliferation is induced in colon adenomas. One possibility is that low, nondetectable nuclear amounts of ß-catenin are sufficient to induce proliferation genes like cyclin D1, and high amounts are necessary to derepress genes associated with tumor progression. Alternatively, both ß-catenin and c-myc may not be directly associated with the induction of proliferation but with later steps in tumor progression. For instance, c-myc overexpression has been described as promoting genomic instability, thereby increasing the rate of genetic alterations.15 More than 80% of colorectal adenomas have APC gene defects as an initial event, leading to an increase of the cytoplasmatic free pool of ß-catenin. However, our results demonstrate that early adenomas do not express detectable amounts of nuclear ß-catenin. It is expected that there are ß-catenin-independent effects of mutated APC. One could speculate that induction of proliferation is one of these ß-catenin independent functions of mutated APC. It is interesting that, in a recent publication, Samowitz et al reported that dominant, active mutations in the ß-catenin gene, which also lead to a reduced degradation of ß-catenin and are associated with normal APC, are more often found in small, early adenomas than in late adenomas and colorectal carcinomas.10 Particularly, there seemed to be a threshold adenoma size of about 5 mm, above which the rate of ß-catenin mutations rapidly decreases. This is exactly the size above which we defined an increase of nuclear ß-catenin (see discussion below). This could mean that low amounts of nuclear ß-catenin, perhaps enough to induce proliferation, can be found on the basis of both ß-catenin and APC mutations. However, a further increase of nuclear ß-catenin, potentially necessary for tumor progression (see discussion below), could not be achieved simply by mutated ß-catenin, but would need mutant APC as basic genetic alteration. This implies further functions of mutant APC in addition to simple reduction of ß-catenin degradation.
The most stringent correlation we found was between adenoma size and the nuclear expression of ß-catenin and c-myc (P < 0.001), which was higher than the already described correlation between the grade of dysplasia and nuclear ß-catenin (P < 0.005).11 Thus the already high correlation of nuclear ß-catenin with dysplasia can be based mainly on the strong dependence of the dysplasia grade on adenoma size. This observation could be simply explained by a bystander effect, in which genetic alterations leading to an increase of tumor size and progression also lead to an increase of nuclear ß-catenin without a functional consequence. However, it is more likely that nuclear ß-catenin is necessary for exceeding a certain tumor size. The observed sharp size boundaries for low or absent (<5 mm) and medium to high (>8 mm) nuclear expression of ß-catenin, with a transition size between 5 and 8 mm, support this hypothesis. What could be the role of ß-catenin for the transition above this certain adenoma size level? It is known that this is also a critical threshold for the supply of tumors by pre-existing blood vessels. Beyond this size, colon adenomas increase in blood vessel density.16 It is tempting to speculate that high amounts of nuclear ß-catenin derepress genes necessary for tumor angiogenesis and subsequent progression. There are already other recently defined target genes of ß-catenin involved in later steps of colorectal carcinogenesis. We and others have described the activation of the matrix metalloproteinase matrilysin, which is important for tumor growth and invasion by ß-catenin in colorectal cancers.6,7 Also, CD44,17 fibronectin,18 and the urokinase-type plasminogen activator receptor,19 important factors for invasion or metastasis, are potential target genes of ß-catenin/TCF. Thus, we would suggest that nuclear ß-catenin is responsible for the progression of colorectal carcinogenesis, not only by affecting the grade of dysplasia but also exceeding a certain threshold tumor size.
One question that remains is how nuclear ß-catenin increases during
adenoma progression. One possibility is that, based on the APC gene
defect, additional genetic alterations lead to a redistribution of the
membranous or cytoplasmatic pool to the nucleus. Both dominant
ras mutations20
and E-cadherin gene
defects7
are described to have an influence on the
ß-catenin localization and activity. Dominant K-ras gene
mutations are found in about 50% of colon adenomas >10 mm in size and
are correlated with the adenoma size like the expression of nuclear
ß-catenin.21
However, the nuclear overexpression of
ß-catenin, both in late adenomas and colon carcinomas, is
heterogenous9
and often found in contact zones to the
extracellular matrix.8
This also implies that
extracellular matrix-induced epigenetic modulations may be responsible
for the nuclear translocation of ß-catenin in larger adenomas. For
instance, the integrin-linked kinase, which is associated with the
5/ß1 integrin fibronectin receptor, was shown to induce nuclear
translocation of ß-catenin.22
Further work will show
whether K-ras mutations or the expression of the
5/ß1-integrin is also strongly correlated with the size of
colorectal adenomas.
Our results, demonstrating a strong correlation of nuclear ß-catenin and c-myc with adenoma size, but not with proliferative activity, imply that i) APC mutations have additional ß-catenin-independent functions; ii) APC mutations alone are not sufficient for nuclear overexpression of ß-catenin; and iii) nuclear ß-catenin has additional important functions for exceeding a threshold tumor size.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
T. B. and K. H. contributed equally to this publication.
Accepted for publication November 29, 1999.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
 |
|
 |
|
  Y. Bian, T. J. Knobloch, M. Sadim, V. Kaklamani, A. Raji, G.-Y. Yang, C. M. Weghorst, and B. Pasche Somatic acquisition of TGFBR1*6A by epithelial and stromal cells during head and neck and colon cancer development Hum. Mol. Genet., December 15, 2007; 16(24): 3128 - 3135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Misikangas, A.-M. Pajari, E. Paivarinta, S. I. Oikarinen, J. Rajakangas, M. Marttinen, H. Tanayama, R. Torronen, and M. Mutanen Three Nordic Berries Inhibit Intestinal Tumorigenesis in Multiple Intestinal Neoplasia/+ Mice by Modulating {beta}-Catenin Signaling in the Tumor and Transcription in the Mucosa J. Nutr., October 1, 2007; 137(10): 2285 - 2290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Vignjevic, M. Schoumacher, N. Gavert, K.-P. Janssen, G. Jih, M. Lae, D. Louvard, A. Ben-Ze'ev, and S. Robine Fascin, a Novel Target of {beta}-Catenin-TCF Signaling, Is Expressed at the Invasive Front of Human Colon Cancer Cancer Res., July 15, 2007; 67(14): 6844 - 6853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Gumireddy, F. Sun, A. J. Klein-Szanto, J. M. Gibbins, P. A. Gimotty, A. J. Saunders, P. G. Schultz, and Q. Huang In vivo selection for metastasis promoting genes in the mouse PNAS, April 17, 2007; 104(16): 6696 - 6701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R.E. Rees, B. A. Onwuegbusi, V. E. Save, D. Alderson, and R. C. Fitzgerald In vivo and In vitro Evidence for Transforming Growth Factor-{beta}1-Mediated Epithelial to Mesenchymal Transition in Esophageal Adenocarcinoma Cancer Res., October 1, 2006; 66(19): 9583 - 9590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Mulholland, S. Dedhar, G. A. Coetzee, and C. C. Nelson Interaction of Nuclear Receptors with the Wnt/{beta}-Catenin/Tcf Signaling Axis: Wnt You Like to Know? Endocr. Rev., December 1, 2005; 26(7): 898 - 915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Koch, A. Waha, W. Hartmann, A. Hrychyk, U. Schuller, A. Waha, K. A. Wharton Jr, S. Y. Fuchs, D. v. Schweinitz, and T. Pietsch Elevated Expression of Wnt Antagonists Is a Common Event in Hepatoblastomas Clin. Cancer Res., June 15, 2005; 11(12): 4295 - 4304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Baldus, S. P. Monig, S. Huxel, S. Landsberg, F.-G. Hanisch, K. Engelmann, P. M. Schneider, J. Thiele, A. H. Holscher, and H. P. Dienes MUC1 and Nuclear {beta}-Catenin Are Coexpressed at the Invasion Front of Colorectal Carcinomas and Are Both Correlated with Tumor Prognosis Clin. Cancer Res., April 15, 2004; 10(8): 2790 - 2796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yamada and H. Mori Pre-cancerous lesions for colorectal cancers in rodents: a new concept Carcinogenesis, June 1, 2003; 24(6): 1015 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Chilosi, V. Poletti, A. Zamo, M. Lestani, L. Montagna, P. Piccoli, S. Pedron, M. Bertaso, A. Scarpa, B. Murer, et al. Aberrant Wnt/{beta}-Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis Am. J. Pathol., May 1, 2003; 162(5): 1495 - 1502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kotsinas, K. Evangelou, P. Zacharatos, C. Kittas, and V. G. Gorgoulis Proliferation, but Not Apoptosis, Is Associated with Distinct {beta}-Catenin Expression Patterns in Non-Small-Cell Lung Carcinomas : Relationship with Adenomatous Polyposis Coli and G1-to S-Phase Cell-Cycle Regulators Am. J. Pathol., November 1, 2002; 161(5): 1619 - 1634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhai, R. Wu, D. R. Schwartz, D. Darrah, H. Reed, F. T. Kolligs, M. T. Nieman, E. R. Fearon, and K. R. Cho Role of {beta}-Catenin/T-Cell Factor-Regulated Genes in Ovarian Endometrioid Adenocarcinomas Am. J. Pathol., April 1, 2002; 160(4): 1229 - 1238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Abraham, T.-T. Wu, R. H. Hruban, J.-H. Lee, C. J. Yeo, K. Conlon, M. Brennan, J. L. Cameron, and D. S. Klimstra Genetic and Immunohistochemical Analysis of Pancreatic Acinar Cell Carcinoma : Frequent Allelic Loss on Chromosome 11p and Alterations in the APC/{beta}-Catenin Pathway Am. J. Pathol., March 1, 2002; 160(3): 953 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, Y. Xiao, Y. Mou, Y. Zhao, W. M. Blankesteijn, and J. L. Hall A Role for the {beta}-Catenin/T-Cell Factor Signaling Cascade in Vascular Remodeling Circ. Res., February 22, 2002; 90(3): 340 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. C. S. Wong and M. Pignatelli {beta}-Catenin--A Linchpin in Colorectal Carcinogenesis? Am. J. Pathol., February 1, 2002; 160(2): 389 - 401. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jung, M. Schrauder, U. Oswald, C. Knoll, P. Sellberg, R. Palmqvist, G. Niedobitek, T. Brabletz, and T. Kirchner The Invasion Front of Human Colorectal Adenocarcinomas Shows Co-Localization of Nuclear {beta}-Catenin, Cyclin D1, and p16INK4A and Is a Region of Low Proliferation Am. J. Pathol., November 1, 2001; 159(5): 1613 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Lifschitz-Mercer, R. Amitai, B. B.-S. Maymon, L. Shechtman, B. Czernobilsky, L. Leider-Trejo, A. Ben-Ze'ev, and B. Geiger Nuclear Localization of {beta}-Catenin and Plakoglobin in Primary and Metastatic Human Colonic Carcinomas, Colonic Adenomas, and Normal Colon International Journal of Surgical Pathology, October 1, 2001; 9(4): 273 - 279. [Abstract] [PDF]
|
|
|
|
|
|
T. Brabletz, A. Jung, S. Reu, M. Porzner, F. Hlubek, L. A. Kunz-Schughart, R. Knuechel, and T. Kirchner Variable beta -catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment PNAS, August 28, 2001; 98(18): 10356 - 10361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Persad, A. A.Troussard, T. R. McPhee, D. J. Mulholland, and S. Dedhar Tumor Suppressor PTEN Inhibits Nuclear Accumulation of {beta}-Catenin and T Cell/Lymphoid Enhancer Factor 1-mediated Transcriptional Activation J. Cell Biol., June 4, 2001; 153(6): 1161 - 1174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Murphy, K. R. Nielson, and K. H. Albertine Defining a Molecularly Normal Colon J. Histochem. Cytochem., May 1, 2001; 49(5): 667 - 668. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Yamada, N. Yoshimi, Y. Hirose, K. Matsunaga, M. Katayama, K. Sakata, M. Shimizu, T. Kuno, and H. Mori Sequential Analysis of Morphological and Biological Properties of {beta}-Catenin-accumulated Crypts, Provable Premalignant Lesions Independent of Aberrant Crypt Foci in Rat Colon Carcinogenesis Cancer Res., March 1, 2001; 61(5): 1874 - 1878. [Abstract] [Full Text]
|
|
|
|
|
|
G. Garcia-Rostan, R. L. Camp, A. Herrero, M. L. Carcangiu, D. L. Rimm, and G. Tallini {beta}-Catenin Dysregulation in Thyroid Neoplasms : Down-Regulation, Aberrant Nuclear Expression, and CTNNB1 Exon 3 Mutations Are Markers for Aggressive Tumor Phenotypes and Poor Prognosis Am. J. Pathol., March 1, 2001; 158(3): 987 - 996. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Yanagisawa, T. Mikami, M. Saegusa, and I. Okayasu More Frequent {beta}-Catenin Exon 3 Mutations in Gallbladder Adenomas Than in Carcinomas Indicate Different Lineages Cancer Res., January 1, 2001; 61(1): 19 - 22. [Abstract] [Full Text]
|
|
|
|
|
|
T. Kirchner and T. Brabletz Patterning and Nuclear {beta}-Catenin Expression in the Colonic Adenoma-Carcinoma Sequence : Analogies with Embryonic Gastrulation Am. J. Pathol., October 1, 2000; 157(4): 1113 - 1121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wang, Y. Xiao, Y. Mou, Y. Zhao, W. M. Blankesteijn, and J. L. Hall A Role for the {beta}-Catenin/T-Cell Factor Signaling Cascade in Vascular Remodeling Circ. Res., February 22, 2002; 90(3): 340 - 347. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
